Bruker Announces Acquisition of Integrated Proteomics Pipeline (IP2) Software Platform for Large Cohort Translational Studies
September 30 2020 - 07:00AM
Business Wire
IP2 Accelerates CCS-enabled 4D-Proteomics™
with GPU-based Scalable Search Engine
IP2 Adds ‘Run & Done’ Real-Time
Capabilities to timsTOF® Proteomics Systems
Bruker Corporation (Nasdaq: BRKR) announces the recent
acquisition of the Integrated Proteomics Pipeline (IP2) search
engine and proteomics workflow software platform. IP2 was developed
by Integrated Proteomics Applications Inc, a company founded by
leading proteomics researcher Professor John Yates III, together
with Drs. Robin Park and Tao Xu. Financial details of the
transaction were not disclosed.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200930005135/en/
Prof. John Yates III, The Scripps
Research Institute (Photo: Business Wire)
This acquisition further enhances Bruker’s solutions for
CCS-enabled 4D-Proteomics™ by adding fast, scalable and GPU-based
search engine capabilities for faster data processing and full
utilization of molecular collision cross sections (CCS). Benefits
include greater data completeness and higher confidence in protein
and PTM identification and quantification in unbiased ‘shot-gun’
proteomics. Bruker’s novel timsTOF mass spectrometry systems with
>120 Hz duty cycle in PASEF mode are uniquely suitable for
real-time search by GPU-enabled, parallel operations on multiple
threads.
“Partnering with the IP2 team and the Yates Lab provides an
excellent opportunity to enhance Bruker’s bioinformatics
capabilities in support of 4D-Proteomics™,” said Dr. Rohan A.
Thakur, Bruker’s Executive Vice President for Life Science
Mass Spectrometry. “High-throughput proteomics requires
unprecedented search engine performance, including the need for low
false discovery rates with very large datasets. This will benefit
the proteomics research and translational medical community. We are
also pleased to announce the establishment of Bruker’s
bioinformatics team focused on protein and data science based in
San Diego, California, headed by Robin Park who joined Bruker as
part of the IP2 asset acquisition. Robin will continue to work
closely with the Yates Lab in his new role with Bruker, as well as
with other Bruker open proteomics software partners and
collaborators.”
“We are very pleased to partner with Bruker in enabling a
CCS-aware bioinformatics platform,” added Professor John Yates III,
the Ernest W. Hahn Professor at The Scripps Research Institute in
La Jolla, California. “Innovative software tools are a necessity to
address unanswered biological questions with mass spectrometry. The
trapped ion mobility functionality and the robustness of the
timsTOF Pro offer unique bottom-up proteomics capabilities that can
be effectively used to study many diseases. For example, a current
focus of our research is to further our understanding of proteins
involved with brain disorders, such as Alzheimer’s Disease (AD) and
Autism Spectrum Disorders (ASD).”
“The timsTOF has ushered in the era of fast nano-LC, making
greater than fifty 4D-Proteomics™ runs per day per instrument
routine, but pushing the bottleneck downstream to data analysis,”
said Dr. Gary Kruppa, Bruker’s Vice President for
Proteomics. “The unique IP2 GPU search engine, with its capability
to scale with massive data quantities on large cohorts, enables
‘Run & Done’ proteomics, with results available immediately
after a large dataset is acquired. Moreover, with IP2 we expect to
enable a new paradigm where timsTOF acquisition takes search
results as feedback in real time to focus on proteins of interest
for even more complete quantitative results. Finally, IP2 offers an
optional gateway for our other proteomics software partners to
accelerate their time-to-results.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
About the Yates Lab at TSRI (La Jolla, CA)
Research in the Yates lab is focused on the development and
application of mass spectrometry-based proteomics techniques to a
wide range of biological questions. Our lab has been instrumental
in the evolution of the field to its current status, having
pioneered many of the landmark advances that form the basis for
prevailing proteomics practices, including shotgun proteomics
(McCormack, A. L.; Schieltz, D. M.; Goode, B.; Yang, S.; Barnes,
G.; Drubin, D.; Yates, J. R., III. Anal. Chem. 1997, 69, 767−776),
database searching (SEQUEST, Eng, J. K.; McCormack, A. L.; Yates,
J. R., III. J. Am. Soc. Mass Spectrom. 1994, 5, 976−989), and
Multidimensional Protein Identification (MudPIT, Washburn, M. P.;
Wolters, D.; Yates, J. R., III. Nat. Biotechnol. 2001, 19,
242−247). We continue the drive to increase the scope, sensitivity
and throughput of proteomics technologies and their application to
biological questions. Our research encompasses the areas of
bioinformatics and software development, methods development and
biological applications. The integration of all the elements in the
proteomics pipeline within one lab facilitates advances in all of
them. The Yates lab has published more than 700 peer reviewed
papers. Recent highlights include comprehensive proteomics studies
revealing molecular mechanisms implicated in Cystic Fibrosis as
well as identification of proteins capable of restoring function to
mutated proteins in the disease, and investigations into affective
disorders of the brain, including schizophrenia and depression.
http://fields.scripps.edu/yates/wp/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200930005135/en/
Investor Contact: Miroslava Minkova Bruker Director,
Investor Relations & Corporate Development T: +1 (978) 663-3660
x1479 E: Investor.Relations@bruker.com
Media Contact: Dr.
Petra Scheffer Bruker
Daltonics Marketing &
Communications T: +49
(421) 2205-2843 E: petra.scheffer@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Mar 2023 to Mar 2024